share_log

CASI Pharmaceuticals Discloses Material Development Relating To Its Dispute With Juventas

Benzinga ·  Apr 8 17:03

On April 8, 2024, CASI Pharmaceuticals, announced that, with respect to the Company's previously announced dispute with Juventas Cell Therapy Ltd., an emergency arbitrator appointed by the Hong Kong International Arbitration Centre (the "HKIAC") issued an Order on April 5, 2024, granting the emergency injunctive relief CASI sought pending the determination of the arbitration proceeding initiated with the HKIAC in connection with the dispute (the "Arbitration Proceeding"). The emergency arbitrator's Order, among other things, prohibits Juventas from commercializing CNCT19 by itself or through another third party. The emergency arbitrator also noted in the Order that the parties shall cooperate to reach a temporary arrangement that allows them to provide CNCT19 to new patients.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment